Internal Medicine, Endocrinology, Diabetes, & Metabolism · Long Beach, CA
NPI
1306981196
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
3610 Long Beach Blvd Ste 101
Long Beach, CA, 90807
Phone (562) 634-9802
Groups this clinician bills Medicare through
Medicare paid, 2024
$201K
2,192 services
Medicare patients, 2024
605
Average age 68
Drug cost, 2024
$4.1M
11,941 prescriptions
Company payments, 2025
$2,488
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Diana Echeverry-Franck was code 99214 (office e&m - established), 1,499 times for 558 patients. In total Diana Echeverry-Franck billed 2,192 services in 24 codes, and Medicare paid $201K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,499 | 558 | $95.25 | $143K |
| 99204 Office E&M - New | Office | 150 | 150 | $114.31 | $17K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 147 | 74 | $50.92 | $7,485 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 66 | 61 | $12.99 | $857 |
| 76536 Ultrasound - Nonspecific | Office | 55 | 48 | $86.90 | $4,780 |
| 99213 Office E&M - Established | Office | 43 | 40 | $65.85 | $2,831 |
| 93880 Duplex Scan - Extracranial Arteries | Office | 37 | 36 | $133.31 | $4,933 |
| 93970 Duplex Scan - Extremity Veins | Office | 34 | 33 | $127.22 | $4,326 |
| 93978 Duplex Scan - Extremity Arteries | Office | 34 | 33 | $123.04 | $4,183 |
| 93925 Duplex Scan - Extremity Arteries | Office | 34 | 33 | $194.30 | $6,606 |
| 93923 Duplex Scan - Extremity Arteries | Office | 34 | 33 | $70.51 | $2,397 |
| 95251 Test - Miscellaneous | Office | 28 | 22 | $27.16 | $761 |
By year: 2022 $225K for 2,306 services; 2023 $190K for 1,929 services; 2024 $201K for 2,192 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83037 Blood Count | 20 | 19 | $9.60 | $192 |
Medicare prescription drug claims, 2024
In 2024, the drug Diana Echeverry-Franck prescribed most often to Medicare patients was Levothyroxine Sodium, with 716 prescriptions and refills. In total Diana Echeverry-Franck wrote 11,941 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 716 | 1,894 | 211 | $9,542 |
| Metformin Hcl Generic | 623 | 1,658 | 208 | $5,808 |
| Jardiance Empagliflozin | 507 | 1,008 | 140 | $551K |
| Mounjaro Tirzepatide | 429 | 539 | 78 | $538K |
| Trulicity Dulaglutide | 394 | 590 | 91 | $537K |
| Ozempic Semaglutide | 378 | 481 | 73 | $433K |
| Glipizide Generic | 333 | 805 | 110 | $2,989 |
| Atorvastatin Calcium Generic | 285 | 694 | 87 | $2,644 |
| Farxiga Dapagliflozin Propanediol | 285 | 511 | 71 | $272K |
| Rosuvastatin Calcium Generic | 275 | 722 | 94 | $6,978 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 250 | 507 | 70 | $32K |
| Pioglitazone Hcl Generic | 238 | 657 | 77 | $3,551 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 218 | 461 | 93 | $20K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 194 | 364 | 54 | $71K |
| Humalog Kwikpen U-100 Insulin Lispro | 188 | 396 | 56 | $39K |
Brand drugs: 4,528 claims; generic drugs: 6,674 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Diana Echeverry-Franck $2,488 ($2,488 in general payments such as food, travel and fees) from 18 companies. The largest payer was Dexcom, Inc. with $675.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 17 | $675 |
| Amgen Inc. AMGN | 10 | $537 |
| Abbott Laboratories ABT | 10 | $419 |
| Novo Nordisk Inc NVO | 16 | $209 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 12 | $190 |
| Beta Bionics, Inc. BBNX | 5 | $112 |
| Lilly USA, LLC LLY | 2 | $45.85 |
| Recordati_rare_diseases_inc. | 1 | $36.58 |
| Ionis Pharmaceuticals, Inc. IONS | 1 | $33.36 |
| IBSA Pharma Inc. | 2 | $32.11 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.